Document:

<PAGE>

                                                            Exhibit 10.14

                                January 21, 1999

OrthoLogic Corporation
1275 West Washington Street
Tempe, AZ 85281

Ladies and Gentlemen:

         By this Letter of Amendment (the "LOA") it is understood that
OrthoLogic Corp., ("OrthoLogic") and Chrysalis BioTechnology, Inc. ("Chrysalis")
agree to modify their original Definitive Agreement regarding the TP508 (or
Chrysalin) technology ("Technology") for orthopedic applications signed by the
two parties as of December 31, 1997 and amended on September 23, 1998 (the
"Agreement"). The parties agree to amend the Agreement as follows:

         1.       Extension of Worldwide Fracture Application License Option.
Chrysalis and OrthoLogic agree to extend the exercise date for the option for
worldwide (excluding the United States) rights for fracture applications
described in Section IV(b) of the Definitive Agreement until on or before June
30, 1999.

         2.       Linking of International Rights. The worldwide (excluding the
United States) option for fracture applications as described in Section IV(b) of
the Definitive Agreement and the worldwide (excluding the United States) option
for other Orthopedic Applications as defined in Section IV(d) of the Definitive
Agreement, can no longer be exercised independently. Therefore, if OrthoLogic
determines to proceed, it shall pay $1.25 million on or before June 30, 1999 for
the rights to all Orthopedic Applications worldwide (excluding the United
States).

         3.       Other Payments. All other payments due to Chrysalis will be
made by OrthoLogic by the dates specified in the Definitive Agreement. The
timing and amounts of all other milestone payments shall remain unchanged.

         4.       Limited Modification. Except as modified herein, all terms and
conditions of the original Definitive Agreement shall remain in full force and
effect.

         5.       Counterparts. This LOA may be executed by facsimile or manual
signatures. It may be executed in several counterparts, each of which shall be
deemed an original, but such counterparts shall together constitute one
agreement.

                                            Chrysalis BioTechnology, Inc.

                                            By:  /s/ Darrell H. Carney
                                                 -------------------------------
                                                 Darrell H. Carney, Ph.D.
                                                 Title:  President

<PAGE>

OrthoLogic Corporation
January 21, 1999
Page 2

                                   ACCEPTANCE

         The foregoing LOA correctly sets forth our agreement concerning the
Amendments to the Definitive Agreement.

Dated:  January 27, 1999

                                      OrthoLogic Corporation

                                      By: /s/ Thomas R. Trotter
                                          -------------------------------------
                                          Thomas R. Trotter
                                          Title:  President/CEO<PAGE>

                                                                Exhibit 10.15

                 SECOND AMENDMENT TO AGREEMENT BETWEEN CHRYSALIS
                          BIOTECHNOLOGY AND ORTHOLOGIC

         This Second Amendment ("Second Amendment") to Agreement dated December
31, 1997 (the "Agreement") is entered into effective as of the sixth day of
July, 2001, by and between ORTHOLOGIC CORP., a Delaware corporation having a
principal place of business at 1275 West Washington Street, Tempe, Arizona 85281
("OrthoLogic") and CHRYSALIS BIOTECHNOLOGY, INC., a Delaware corporation, having
a principal place of business at 2200 Market, Suite 600, Galveston, Texas 77550
("Chrysalis").

         WHEREAS, OrthoLogic and Chrysalis are parties to the above-referenced
Agreement (as amended by Letters of Amendment dated September 23, 1998 and
January 21, 1999, hereafter referred to as the "Agreement"), which Agreement
provided OrthoLogic with certain rights and options to license certain
technology from Chrysalis;

         WHEREAS, OrthoLogic and Chrysalis entered into the Marketing and
Distribution Agreement as of January 19, 1998 and an amendment to the Agreement
effective July 12, 2000 (the "First Amendment"), which First Amendment expanded
certain territories and markets and provided certain other rights to OrthoLogic
in exchange for certain agreements; and

         WHEREAS, it is the desire of OrthoLogic and Chrysalis to amend certain
other aspects of the rights relating to the Orthopedic Soft Tissue Indications
and International Rights, as defined in the Agreement, as amended, and extend
certain deadlines for OrthoLogic relating to its obligation to obtain a
Marketing Partner, as defined in the Agreement, as amended, all on the terms
contained herein;

         NOW, THEREFORE, in consideration of the above and the agreements
provided herein, the parties hereby agree to amend the Agreement, as previously
amended, as follows:

         Section 1. Option Fee. OrthoLogic hereby agrees to pay to Chrysalis the
sum of $1,000,000 (U.S.), on or before July 6, 2001 (the "Option Fee"), which
Option Fee shall be made in immediately available funds and paid to the account
designated by Chrysalis herein:

                  Mellon Bank
                  Pittsburgh, PA
                  ADA #043000261
                  FBO Merrill Lynch Acct. #101173012
                  For credit to Chrysalis BioTechnology Acct #51807463

Such Option Fee shall be nonrefundable by Chrysalis and shall constitute full
payment for the rights granted to OrthoLogic in this Second Amendment.

         Section 2. Exercise of International Rights. In consideration of the
payment of the Option Fee pursuant to the terms of Section 1 of this Second
Amendment, and the other agreements contained in this Second Amendment,
OrthoLogic and Chrysalis hereby agree that Section 2.11.2 of the Agreement is
hereby deleted, and in lieu thereof, the following is inserted:

<PAGE>

                  "2.11.2. OrthoLogic shall obtain a marketing and distribution
         partner with worldwide sales capabilities prior to NDA filing in the
         United States or equivalent filing in Europe or Asia, whichever is
         earlier, and will use its Reasonable Best Efforts to expedite the
         filing of the NDA in the United States and make the equivalent filing
         in Europe and Asia. For purposes of this Second Amendment, the term
         "Reasonable Best Efforts" shall mean best efforts in accordance with
         reasonable commercial practice."

         Section 3. Amendment to Spinal Fusion Terms. Section IV(e)(v)(2) of the
Agreement is hereby modified by deleting the words, "If within fifteen (15)
months of signing the Amendment," and replacing them as follows "If by December
31, 2001,".

         Section 4. Amendment to International Rights. Section IV(e)(vii) of the
Agreement is hereby amended by inserting the phrase ", alone or in conjunction
with," in lieu of the word "and" in the second line thereof; inserting the word
"Best" immediately following the word "Reasonable" in the second line thereof;
and deleting the phrase "(if exercising its option)" from the fourth line
thereof.

         Section 5. Orthopedic Soft Tissue Exercise. In consideration of the
payment of the Option Fee pursuant to the terms of Section 1 of this Second
Amendment, and the other agreements contained in this Second Amendment,
OrthoLogic and Chrysalis hereby agree that the Option granted to OrthoLogic in
Section IV(e)(vi) of the Agreement for the Orthopedic Soft Tissue Indications is
hereby exercised, and OrthoLogic hereby agrees to assume the related obligations
contained in Section IV(e)(vi) of the Agreement, except that both OrthoLogic and
Chrysalis agree to delay the requirement contained therein that OrthoLogic shall
have secured a Marketing Partner by the date specified therein. The parties
agree that OrthoLogic shall obtain a Marketing Partner prior to NDA filing in
the United States or equivalent filing in Europe or Asia, whichever is earlier,
and that OrthoLogic will use its Reasonable Best Efforts to expedite the NDA or
equivalent filling to the greatest extent practicable.

         Section 6. Right to Audit. In connection with the provisions contained
in this Second Amendment, Chrysalis shall have the right to review and audit the
activities and records of OrthoLogic relating to OrthoLogic's obligations to use
its Reasonable Best Efforts to make such filings and obtain such approvals, in
order to assure itself that OrthoLogic has complied therewith. Such right may be
exercised at such times as Chrysalis shall reasonably request.

         Section 7. No Other Changes. Except as amended hereby, all of the terms
and conditions of the Agreement and all of the definitions contained therein
shall remain unchanged and unaffected by this Second Amendment.

         Section 8. Counterparts. This Second Amendment may be executed in one
or more counterparts, each of which shall be deemed an original but all of
which, taken together, shall constitute one and the same instrument.

                                      - 2 -
<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Second Amendment as
of the date set out above, to be effective upon receipt by Chrysalis of the
Option Fee provided in Section 1 above.

                                            ORTHOLOGIC CORP.

                                            By: /s/ Tom Trotter
                                                --------------------------------
                                                Tom Trotter, President

                                            CHRYSALIS BIOTECHNOLOGY, INC.

                                            By: /s/ Darrell H. Carney
                                                -------------------------------
                                                Darrell H. Carney, President

                                      - 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]